HLN:NYE-Haleon plc (USD)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 10.29

Change

+0.13 (+1.28)%

Market Cap

USD 46.39B

Volume

2.34M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-04 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
ZTS Zoetis Inc

N/A

USD 83.17B
TAK Takeda Pharmaceutical Co Ltd A..

N/A

USD 47.69B
RDY Dr. Reddy’s Laboratories Ltd..

N/A

USD 13.37B
CTLT Catalent Inc

N/A

USD 10.83B
ELAN Elanco Animal Health

N/A

USD 7.59B
AMRX Amneal Pharmaceuticals, Inc. C..

N/A

USD 2.67B
BHC Bausch Health Companies Inc

N/A

USD 2.33B
CPHI China Pharma Holdings Inc

N/A

USD 3.04M
YCBD cbdMD Inc

N/A

USD 2.14M
PBH Prestige Brand Holdings Inc

N/A

N/A

ETFs Containing HLN

XS3R:LSE Xtrackers MSCI Europe Con.. 5.81 % 0.00 %

N/A

USD 0.06B
DXSK:XETRA Xtrackers - Stoxx Europe .. 5.81 % 0.00 %

N/A

USD 0.07B
FT1K:LSE Amundi MSCI UK IMI SRI PA.. 4.02 % 0.00 %

N/A

N/A
UKSR:LSE UBS Irl plc MSCI United K.. 3.17 % 0.00 %

N/A

USD 0.64B
C1U:PA Amundi FTSE 100 UCITS 3.11 % 0.00 %

N/A

USD 0.04B
ESIS:LSE iShares MSCI Europe Consu.. 3.04 % 0.00 %

N/A

USD 0.61B
ESIS:F Ishares VI PLC - Ishares .. 2.96 % 0.00 %

N/A

USD 0.80B
ESIS:XETRA iShares MSCI Europe Consu.. 2.96 % 0.00 %

N/A

USD 0.58B
CUIK:XETRA Amundi MSCI UK IMI SRI PA.. 2.85 % 0.00 %

N/A

USD 0.18B
CSTP:LSE SPDR® MSCI Europe Consum.. 2.77 % 0.00 %

N/A

USD 0.18B
STS:PA SSgA SPDR ETFs Europe II .. 2.77 % 0.00 %

N/A

USD 0.18B
SPYC:XETRA SPDR® MSCI Europe Consum.. 2.77 % 0.00 %

N/A

USD 0.16B
STSX:SW SPDR® MSCI Europe Consum.. 2.60 % 0.00 %

N/A

USD 0.19B
CSPE:LSE SPDR® MSCI Europe Consum.. 2.44 % 0.00 %

N/A

N/A
EXV4:XETRA iShares STOXX Europe 600 .. 1.80 % 0.00 %

N/A

USD 0.70B
SXDPEX:SW iShares STOXX Europe 600 .. 1.71 % 0.00 %

N/A

USD 0.44B
DXSK:F Xtrackers - Stoxx Europe .. 0.00 % 0.00 %

N/A

N/A
EXV4:F iShares STOXX Europe 600 .. 0.00 % 0.00 %

N/A

N/A
SPYC:F SSgA SPDR ETFs Europe II .. 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 25.03% 71% C- 90% A-
Dividend Return 1.92% 71% C- 44% F
Total Return 26.95% 71% C- 90% A-
Trailing 12 Months  
Capital Gain 31.08% 71% C- 87% B+
Dividend Return 2.01% 43% F 31% F
Total Return 33.09% 71% C- 86% B+
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 6.57% N/A N/A 61% D-
Dividend Return 6.95% N/A N/A 55% F
Total Return 0.38% N/A N/A 9% A-
Risk Return Profile  
Volatility (Standard Deviation) 12.07% N/A N/A 72% C
Risk Adjusted Return 57.57% N/A N/A 76% C+
Market Capitalization 46.39B 83% B 95% A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector